The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3679, doi. 10.1038/sj.onc.1210364
- By:
- Publication type:
- Article
Works matching IS 09509232 AND DT 2007 AND VI 26 AND IP 25
Results: 18
1
2
‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3629, doi. 10.1038/sj.onc.1210365
- By:
- Publication type:
- Article
3
Bevacizumab in the treatment of non-small-cell lung cancer.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3691, doi. 10.1038/sj.onc.1210366
- By:
- Publication type:
- Article
4
Guest Editor.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3591, doi. 10.1038/sj.onc.1210367
- Publication type:
- Article
5
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3699, doi. 10.1038/sj.onc.1210368
- By:
- Publication type:
- Article
6
Preface: antibody therapies for cancer.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3592, doi. 10.1038/sj.onc.1210369
- By:
- Publication type:
- Article
7
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3704, doi. 10.1038/sj.onc.1210370
- By:
- Publication type:
- Article
8
Anti-idiotype antibodies in cancer treatment.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3594, doi. 10.1038/sj.onc.1210371
- By:
- Publication type:
- Article
9
Novel antibodies as anticancer agents.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3714, doi. 10.1038/sj.onc.1210372
- By:
- Publication type:
- Article
10
Novel radiolabeled antibody conjugates.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3734, doi. 10.1038/sj.onc.1210373
- By:
- Publication type:
- Article
11
Targeting death-inducing receptors in cancer therapy.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3745, doi. 10.1038/sj.onc.1210374
- By:
- Publication type:
- Article
12
Antibody-targeted vaccines.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3758, doi. 10.1038/sj.onc.1210375
- By:
- Publication type:
- Article
13
Rituximab therapy in malignant lymphoma.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3603, doi. 10.1038/sj.onc.1210376
- By:
- Publication type:
- Article
14
Current role of antibody therapy in patients with metastatic colorectal cancer.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3661, doi. 10.1038/sj.onc.1210377
- By:
- Publication type:
- Article
15
Radioimmunotherapy for B-cell lymphoma: Y<sup>90</sup> ibritumomab tiuxetan and I<sup>131</sup> tositumomab.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3614, doi. 10.1038/sj.onc.1210378
- By:
- Publication type:
- Article
16
Trastuzumab: triumphs and tribulations.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3637, doi. 10.1038/sj.onc.1210379
- By:
- Publication type:
- Article
17
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3644, doi. 10.1038/sj.onc.1210380
- By:
- Publication type:
- Article
18
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
- Published in:
- Oncogene, 2007, v. 26, n. 25, p. 3654, doi. 10.1038/sj.onc.1210381
- By:
- Publication type:
- Article